Investor's Business Daily on MSN20m
Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms
Novo Nordisk stock surged Friday after the obesity kingpin reported strong results for its next-generation weight-loss drug, amycretin.
verywellhealth49m
What's New in Alzheimer's Treatment?
We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...